A detailed history of Man Group PLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 25,692 shares of ESPR stock, worth $57,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,692
Holding current value
$57,550
% of portfolio
0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.61 - $2.73 $41,364 - $70,139
25,692 New
25,692 $42,000
Q1 2024

May 15, 2024

BUY
$2.02 - $3.02 $452,045 - $675,830
223,785 Added 103.13%
440,770 $1.18 Million
Q4 2023

Feb 14, 2024

BUY
$0.73 - $3.08 $122,319 - $516,087
167,561 Added 339.03%
216,985 $648,000
Q3 2023

Nov 14, 2023

SELL
$0.96 - $1.79 $65,113 - $121,410
-67,827 Reduced 57.85%
49,424 $48,000
Q2 2023

Aug 14, 2023

BUY
$1.2 - $1.76 $54,730 - $80,271
45,609 Added 63.66%
117,251 $162,000
Q1 2023

May 15, 2023

BUY
$1.46 - $7.3 $78,171 - $390,856
53,542 Added 295.81%
71,642 $113,000
Q4 2022

Feb 14, 2023

BUY
$5.09 - $8.5 $92,129 - $153,850
18,100 New
18,100 $112,000
Q2 2022

Aug 15, 2022

SELL
$4.77 - $6.67 $313,389 - $438,219
-65,700 Reduced 58.19%
47,203 $300,000
Q1 2022

May 16, 2022

BUY
$3.34 - $5.56 $377,096 - $627,740
112,903 New
112,903 $524,000
Q4 2021

Feb 14, 2022

SELL
$4.81 - $11.92 $75,786 - $187,811
-15,756 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$11.34 - $21.37 $22,430 - $42,269
1,978 Added 14.36%
15,756 $190,000
Q2 2021

Aug 16, 2021

SELL
$19.4 - $28.71 $276,411 - $409,060
-14,248 Reduced 50.84%
13,778 $291,000
Q1 2021

May 17, 2021

SELL
$25.12 - $36.89 $239,996 - $352,447
-9,554 Reduced 25.42%
28,026 $786,000
Q4 2020

Feb 16, 2021

BUY
$24.2 - $35.76 $483,249 - $714,091
19,969 Added 113.39%
37,580 $977,000
Q3 2020

Nov 16, 2020

BUY
$31.18 - $52.71 $8,761 - $14,811
281 Added 1.62%
17,611 $655,000
Q2 2020

Aug 14, 2020

BUY
$30.04 - $51.31 $330,199 - $563,999
10,992 Added 173.43%
17,330 $889,000
Q1 2020

May 15, 2020

SELL
$27.44 - $73.84 $7.59 Million - $20.4 Million
-276,658 Reduced 97.76%
6,338 $200,000
Q4 2019

Feb 18, 2020

BUY
$35.4 - $59.82 $2.7 Million - $4.57 Million
76,369 Added 36.96%
282,996 $16.9 Million
Q3 2019

Nov 14, 2019

SELL
$34.47 - $47.53 $1.79 Million - $2.47 Million
-52,056 Reduced 20.12%
206,627 $7.58 Million
Q2 2019

Aug 14, 2019

BUY
$40.1 - $52.33 $985,096 - $1.29 Million
24,566 Added 10.49%
258,683 $12 Million
Q1 2019

May 15, 2019

BUY
$40.11 - $53.57 $2.82 Million - $3.77 Million
70,331 Added 42.94%
234,117 $9.4 Million
Q4 2018

Feb 14, 2019

BUY
$36.99 - $59.11 $747,863 - $1.2 Million
20,218 Added 14.08%
163,786 $7.54 Million
Q3 2018

Nov 14, 2018

BUY
$40.74 - $51.41 $4.9 Million - $6.19 Million
120,357 Added 518.53%
143,568 $6.37 Million
Q2 2018

Aug 14, 2018

BUY
$36.2 - $76.4 $840,238 - $1.77 Million
23,211 New
23,211 $910,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $149M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.